Comprehensive Stock Comparison
Compare Amicus Therapeutics, Inc. (FOLD) vs BioMarin Pharmaceutical Inc. (BMRN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | FOLD | 32.3% revenue growth vs BMRN's 12.9% |
| Value | BMRN | Lower P/E (15.4x vs 47.4x) |
| Quality / Margins | BMRN | 10.8% net margin vs FOLD's -2.3% |
| Stability / Safety | FOLD | Beta 0.65 vs BMRN's 0.74 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | FOLD | +51.4% vs BMRN's -13.3% |
| Efficiency (ROA) | BMRN | 4.6% ROA vs FOLD's -1.6%, ROIC 7.4% vs 4.8% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Amicus Therapeutics is a biotechnology company that develops and commercializes precision medicines for rare genetic diseases. It generates revenue primarily from sales of Galafold for Fabry disease — its only marketed product — supplemented by research collaborations and milestone payments from partners. The company's competitive advantage lies in its expertise in small molecule chaperone technology and its focused pipeline targeting high-need rare diseases with limited treatment options.
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing therapies for rare genetic diseases. It generates revenue primarily from sales of its orphan drug portfolio — including Voxzogo, Vimizim, and Palynziq — with additional income from licensing and royalties. The company's moat lies in its deep expertise in rare disease biology and its established commercial infrastructure for ultra-orphan drugs, which creates high barriers to entry.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
BMRN leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). FOLD leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Financial Metrics (TTM)
BMRN is the larger business by revenue, generating $3.2B annually — 5.4x FOLD's $599M. BMRN is the more profitable business, keeping 10.8% of every revenue dollar as net income compared to FOLD's -2.3%.
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $599M | $3.2B |
| EBITDAEarnings before interest/tax | $40M | $613M |
| Net IncomeAfter-tax profit | -$14M | $349M |
| Free Cash FlowCash after capex | $10M | $725M |
| Gross MarginGross profit ÷ Revenue | +89.5% | +77.1% |
| Operating MarginEBIT ÷ Revenue | +5.5% | +16.6% |
| Net MarginNet income ÷ Revenue | -2.3% | +10.8% |
| FCF MarginFCF ÷ Revenue | +1.6% | +22.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.5% | +17.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.8% | -134.4% |
Valuation Metrics
On an enterprise value basis, BMRN's 18.2x EV/EBITDA is more attractive than FOLD's 139.5x.
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| Market CapShares × price | $4.4B | $11.9B |
| Enterprise ValueMkt cap + debt − cash | $4.7B | $11.1B |
| Trailing P/EPrice ÷ TTM EPS | -79.83x | 34.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 47.44x | 15.45x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 139.52x | 18.18x |
| Price / SalesMarket cap ÷ Revenue | 8.39x | 3.68x |
| Price / BookPrice ÷ Book value/share | 22.54x | 2.00x |
| Price / FCFMarket cap ÷ FCF | — | 16.36x |
Profitability & Efficiency
BMRN delivers a 5.7% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-6 for FOLD. BMRN carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 2.29x.
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | -6.1% | +5.7% |
| ROA (TTM)Return on assets | -1.6% | +4.6% |
| ROICReturn on invested capital | +4.8% | +7.4% |
| ROCEReturn on capital employed | +4.0% | +7.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 2.29x | 0.10x |
| Net DebtTotal debt minus cash | $230M | -$715M |
| Cash & Equiv.Liquid assets | $214M | $1.3B |
| Total DebtShort + long-term debt | $444M | $597M |
| Interest CoverageEBIT ÷ Interest expense | 1.11x | 48.95x |
Total Returns (with DRIP)
A $10,000 investment in FOLD five years ago would be worth $12,188 today (with dividends reinvested), compared to $7,797 for BMRN. Over the past 12 months, FOLD leads with a +51.4% total return vs BMRN's -13.3%. The 3-year compound annual growth rate (CAGR) favors FOLD at 2.9% vs BMRN's -14.7% — a key indicator of consistent wealth creation.
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | +0.7% | +3.8% |
| 1-Year ReturnPast 12 months | +51.4% | -13.3% |
| 3-Year ReturnCumulative with dividends | +8.9% | -38.0% |
| 5-Year ReturnCumulative with dividends | +21.9% | -22.0% |
| 10-Year ReturnCumulative with dividends | +133.3% | -24.6% |
| CAGR (3Y)Annualised 3-year return | +2.9% | -14.7% |
Risk & Volatility
FOLD is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than BMRN's 0.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs BMRN's 84.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.65x | 0.74x |
| 52-Week HighHighest price in past year | $14.38 | $73.51 |
| 52-Week LowLowest price in past year | $5.51 | $50.76 |
| % of 52W HighCurrent price vs 52-week peak | +99.9% | +84.0% |
| RSI (14)Momentum oscillator 0–100 | 72.0 | 56.6 |
| Avg Volume (50D)Average daily shares traded | 8.1M | 1.9M |
Analyst Outlook
Wall Street rates FOLD as "Buy" and BMRN as "Buy". Consensus price targets imply 32.8% upside for BMRN (target: $82) vs -0.3% for FOLD (target: $14).
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $14.33 | $82.00 |
| # AnalystsCovering analysts | 24 | 40 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Amicus Therapeutics… (FOLD) | 100 | 153.33 | +53.3% |
| BioMarin Pharmaceut… (BMRN) | 100 | 61.39 | -38.6% |
Amicus Therapeutics… (FOLD) returned +22% over 5 years vs BioMarin Pharmaceut… (BMRN)'s -22%. A $10,000 investment in FOLD 5 years ago would be worth $12,188 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Amicus Therapeutics… (FOLD) | $5M | $528M | +10555.4% |
| BioMarin Pharmaceut… (BMRN) | $1.1B | $0.00 | -100.0% |
BioMarin Pharmaceutical Inc.'s revenue grew from $1.1B (2016) to $0M (2025) — a -100.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Amicus Therapeutics… (FOLD) | -40.3% | -10.6% | +73.7% |
| BioMarin Pharmaceut… (BMRN) | -19.3% | 15.0% | +177.5% |
BioMarin Pharmaceutical Inc.'s net margin went from -19% (2015) to 15% (2024).
Chart 4P/E Ratio History — 5 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| BioMarin Pharmaceut… (BMRN) | 19.4 | 424.5 | +2088.1% |
BioMarin Pharmaceutical Inc. has traded in a 19x–425x P/E range over 5 years; current trailing P/E is ~34x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Amicus Therapeutics… (FOLD) | -1.49 | -0.18 | +87.9% |
| BioMarin Pharmaceut… (BMRN) | -3.79 | 0.14 | +103.7% |
BioMarin Pharmaceutical Inc.'s EPS grew from $-3.79 (2016) to $0.14 (2025).
Chart 6Free Cash Flow — 5 Years
Amicus Therapeutics, Inc. generated $-37M FCF in 2024 (+82% vs 2021). BioMarin Pharmaceutical Inc. generated $725M FCF in 2025 (+291% vs 2021).
FOLD vs BMRN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is FOLD or BMRN a better buy right now?
BioMarin Pharmaceutical Inc. (BMRN) offers the better valuation at 34.3x trailing P/E (15.4x forward), making it the more compelling value choice. Analysts rate Amicus Therapeutics, Inc. (FOLD) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FOLD or BMRN?
On forward P/E, BioMarin Pharmaceutical Inc. is actually cheaper at 15.4x.
03Which is the better long-term investment — FOLD or BMRN?
Over the past 5 years, Amicus Therapeutics, Inc. (FOLD) delivered a total return of +21.9%, compared to -22.0% for BioMarin Pharmaceutical Inc. (BMRN). A $10,000 investment in FOLD five years ago would be worth approximately $12K today (assuming dividends reinvested). Over 10 years, the gap is even starker: FOLD returned +133.3% versus BMRN's -24.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FOLD or BMRN?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc. (FOLD) is the lower-risk stock at 0.65β versus BioMarin Pharmaceutical Inc.'s 0.74β — meaning BMRN is approximately 14% more volatile than FOLD relative to the S&P 500. On balance sheet safety, BioMarin Pharmaceutical Inc. (BMRN) carries a lower debt/equity ratio of 10% versus 2% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — FOLD or BMRN?
BioMarin Pharmaceutical Inc. (BMRN) is the more profitable company, earning 10.8% net margin versus -10.6% for Amicus Therapeutics, Inc. — meaning it keeps 10.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16.6% versus 4.7% for FOLD. At the gross margin level — before operating expenses — FOLD leads at 90.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is FOLD or BMRN more undervalued right now?
On forward earnings alone, BioMarin Pharmaceutical Inc. (BMRN) trades at 15.4x forward P/E versus 47.4x for Amicus Therapeutics, Inc. — 32.0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMRN: 32.8% to $82.00.
07Which pays a better dividend — FOLD or BMRN?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is FOLD or BMRN better for a retirement portfolio?
For long-horizon retirement investors, Amicus Therapeutics, Inc. (FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.65), +133.3% 10Y return). Both have compounded well over 10 years (FOLD: +133.3%, BMRN: -24.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between FOLD and BMRN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.